{"id":59591,"date":"2024-06-25T07:04:23","date_gmt":"2024-06-25T05:04:23","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/benevolentai-and-astrazeneca-collaboration-yields-continued-success-as-further-novel-target-progressed-into-portfolio\/"},"modified":"2024-06-25T07:04:23","modified_gmt":"2024-06-25T05:04:23","slug":"benevolentai-and-astrazeneca-collaboration-yields-continued-success-as-further-novel-target-progressed-into-portfolio","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/benevolentai-and-astrazeneca-collaboration-yields-continued-success-as-further-novel-target-progressed-into-portfolio\/","title":{"rendered":"BenevolentAI and AstraZeneca Collaboration Yields Continued Success as Further Novel Target Progressed Into Portfolio"},"content":{"rendered":"<div>\n<p class=\"bwalignc\">\n\u00a0<\/p>\n<p>LONDON&#8211;(BUSINESS WIRE)&#8211;BenevolentAI (\u201cBenevolentAI\u201d or the \u201cCompany\u201d) (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces that AstraZeneca has added a novel target for systemic lupus erythematosus (SLE) to its discovery portfolio through its collaboration with BenevolentAI.<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nSecond target to be selected this year from the extended collaboration with AstraZeneca, highlighting continued positive progress in the field of target identification<\/li>\n<li>\nNovel target for SLE was discovered using BenevolentAI\u2019s AI-drug discovery platform and experimentally validated by AstraZeneca<\/li>\n<\/ul>\n<p>\nBenevolentAI\u2019s strategic collaboration with AstraZeneca began in 2019 in idiopathic pulmonary fibrosis and chronic kidney disease, with the collaboration expanded in January 2022 to include heart failure and SLE. The success today in the extension phase of the collaboration follows the announcement last month that AstraZeneca had selected a novel heart failure target to enter its portfolio and further demonstrates how the Benevolent Platform<sup>TM<\/sup> can be applied across multiple therapeutic areas.<\/p>\n<p>\nThe strength of the collaboration in the identification of novel and robust targets is due to its innovative structure combining AstraZeneca\u2019s scientific and disease-specific expertise with BenevolentAI\u2019s AI-driven drug discovery platform and biomedical knowledge. As with the initial collaboration with AstraZeneca, the 2022 extension included an upfront payment on signing, as well as research funding alongside discovery, development and commercial milestones, in addition to tiered royalties on net sales of any commercialised products.<\/p>\n<p>\nSLE, or lupus, is a chronic autoimmune disease where the immune system mistakenly identifies the body\u2019s own tissues as foreign. In people with lupus, the immune system creates autoantibodies to attack the body\u2019s own tissues. These autoantibodies form immune complexes causing inflammation, pain and damage \u2013 often affecting the organs and joints in severe cases. Extreme fatigue and cognitive issues are also common, along with comorbidities including cardiovascular disease. Lupus disproportionately affects females and people of Asian, Black African and Caribbean heritage.<\/p>\n<p>\n<b>Dr Anne Phelan, Chief Scientific Officer of BenevolentAI, said:<\/b><\/p>\n<p>\n<i>\u201cFollowing our recent success in the area of heart failure, I\u2019m delighted that AstraZeneca has selected a novel target for SLE to enter its portfolio. The continued, fruitful efforts of our two companies working in collaboration will help bring potential new therapeutic options to lupus patients, whose quality of life is often severely limited by the disease.\u201d<\/i><\/p>\n<p>\n<b>Prof Maria Belvisi, SVP and Head of Research and Early Development Respiratory and Immunology at AstraZeneca said:<\/b><\/p>\n<p>\n<i>\u201cOur aim is to lead in lupus by continuing to discover and develop novel treatments that push the efficacy ceiling for patients, allowing more people to achieve remission. By combining our immunology disease area expertise and BenevolentAI\u2019s AI-driven discovery platform, we are increasing our ability to identify new targets based on patient insights, complementing our portfolio of potential treatments for this debilitating disease.\u201d<\/i><\/p>\n<p>\nCategory: non-regulatory<\/p>\n<p>\n<b>About BenevolentAI<\/b><\/p>\n<p>\nAt BenevolentAI (AMS: BAI), we serve patients by leveraging our proprietary and validated Benevolent Platform\u2122 that integrates AI and science to uncover new biology, predict novel targets and develop first-in-class or best-in-class drugs for complex diseases. By applying proprietary advanced AI tools, in combination with in-house scientific expertise and wet-lab facilities, BenevolentAI is well-positioned to identify and accelerate novel drug discovery.<\/p>\n<p>\nThe Company\u2019s business model presents multiple routes for value creation including discovery collaborations with pharma companies like AstraZeneca and Merck and advancing in-house pipelines to inflection points. Headquartered in London, with wet labs in Cambridge (UK), BenevolentAI is at the forefront of reshaping the future of drug discovery and delivering innovative medicines.<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>Investors:<\/b><br \/>Catherine Isted \u2013 Chief Financial Officer<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#x61;&#x69;&#x6c;&#x74;&#111;&#58;&#105;&#110;ves&#x74;&#x6f;&#x72;&#x73;&#x40;&#x62;&#101;&#110;&#101;vol&#x65;&#x6e;&#x74;&#x2e;&#x61;&#x69;\" rel=\"nofollow noopener\" shape=\"rect\">inve&#115;&#116;&#111;&#114;&#115;&#64;&#98;&#x65;&#x6e;&#x65;&#x76;&#x6f;&#x6c;&#x65;&#x6e;&#x74;&#46;ai<\/a><br \/>T: +44(0) 203 781 9360<\/p>\n<p>\n<b>Media:<\/b><br \/>James Osborn \u2013 Communications Lead<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;a&#x69;&#108;&#x74;&#111;&#x3a;&#x70;r&#x65;&#115;&#x73;&#64;&#x62;&#101;n&#x65;&#118;&#x6f;&#108;&#x65;&#110;t&#x2e;&#97;&#x69;\" rel=\"nofollow noopener\" shape=\"rect\">&#x70;r&#x65;s&#x73;&#64;&#x62;&#101;n&#x65;v&#x6f;&#108;&#x65;&#110;&#x74;&#46;a&#x69;<\/a><br \/>T: +44(0) 203 781 9360<\/p>\n<p>\n<b>FTI Consulting:<\/b><br \/>Ben Atwell \/ Simon Conway \/ Victoria Foster Mitchell<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#x61;&#x69;&#x6c;&#x74;&#x6f;&#58;&#66;&#101;&#110;evol&#x65;&#x6e;&#x74;&#x41;&#x49;&#x40;&#102;&#116;&#105;&#99;&#111;nsu&#x6c;&#x74;&#x69;&#x6e;&#x67;&#x2e;&#99;&#111;&#109;\" rel=\"nofollow noopener\" shape=\"rect\">&#x42;&#x65;&#110;e&#x76;&#x6f;&#108;en&#x74;&#x41;&#73;&#64;&#x66;&#x74;&#105;&#99;o&#x6e;&#x73;&#117;l&#x74;&#x69;&#110;&#103;&#46;&#x63;&#x6f;&#109;<\/a><br \/>T: +44 203 727 1000<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>\u00a0 LONDON&#8211;(BUSINESS WIRE)&#8211;BenevolentAI (\u201cBenevolentAI\u201d or the \u201cCompany\u201d) (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces that AstraZeneca has added a novel target for systemic lupus erythematosus (SLE) to its discovery portfolio through its collaboration with BenevolentAI. Second target to be selected this year from the extended collaboration with &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/benevolentai-and-astrazeneca-collaboration-yields-continued-success-as-further-novel-target-progressed-into-portfolio\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-59591","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>BenevolentAI and AstraZeneca Collaboration Yields Continued Success as Further Novel Target Progressed Into Portfolio - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/benevolentai-and-astrazeneca-collaboration-yields-continued-success-as-further-novel-target-progressed-into-portfolio\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BenevolentAI and AstraZeneca Collaboration Yields Continued Success as Further Novel Target Progressed Into Portfolio - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"\u00a0 LONDON&#8211;(BUSINESS WIRE)&#8211;BenevolentAI (\u201cBenevolentAI\u201d or the \u201cCompany\u201d) (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces that AstraZeneca has added a novel target for systemic lupus erythematosus (SLE) to its discovery portfolio through its collaboration with BenevolentAI. Second target to be selected this year from the extended collaboration with ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/benevolentai-and-astrazeneca-collaboration-yields-continued-success-as-further-novel-target-progressed-into-portfolio\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2024-06-25T05:04:23+00:00\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/benevolentai-and-astrazeneca-collaboration-yields-continued-success-as-further-novel-target-progressed-into-portfolio\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/benevolentai-and-astrazeneca-collaboration-yields-continued-success-as-further-novel-target-progressed-into-portfolio\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"BenevolentAI and AstraZeneca Collaboration Yields Continued Success as Further Novel Target Progressed Into Portfolio\",\"datePublished\":\"2024-06-25T05:04:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/benevolentai-and-astrazeneca-collaboration-yields-continued-success-as-further-novel-target-progressed-into-portfolio\\\/\"},\"wordCount\":624,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/benevolentai-and-astrazeneca-collaboration-yields-continued-success-as-further-novel-target-progressed-into-portfolio\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/benevolentai-and-astrazeneca-collaboration-yields-continued-success-as-further-novel-target-progressed-into-portfolio\\\/\",\"name\":\"BenevolentAI and AstraZeneca Collaboration Yields Continued Success as Further Novel Target Progressed Into Portfolio - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"datePublished\":\"2024-06-25T05:04:23+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/benevolentai-and-astrazeneca-collaboration-yields-continued-success-as-further-novel-target-progressed-into-portfolio\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/benevolentai-and-astrazeneca-collaboration-yields-continued-success-as-further-novel-target-progressed-into-portfolio\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/benevolentai-and-astrazeneca-collaboration-yields-continued-success-as-further-novel-target-progressed-into-portfolio\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BenevolentAI and AstraZeneca Collaboration Yields Continued Success as Further Novel Target Progressed Into Portfolio\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BenevolentAI and AstraZeneca Collaboration Yields Continued Success as Further Novel Target Progressed Into Portfolio - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/benevolentai-and-astrazeneca-collaboration-yields-continued-success-as-further-novel-target-progressed-into-portfolio\/","og_locale":"en_US","og_type":"article","og_title":"BenevolentAI and AstraZeneca Collaboration Yields Continued Success as Further Novel Target Progressed Into Portfolio - Pharma Trend","og_description":"\u00a0 LONDON&#8211;(BUSINESS WIRE)&#8211;BenevolentAI (\u201cBenevolentAI\u201d or the \u201cCompany\u201d) (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces that AstraZeneca has added a novel target for systemic lupus erythematosus (SLE) to its discovery portfolio through its collaboration with BenevolentAI. Second target to be selected this year from the extended collaboration with ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/benevolentai-and-astrazeneca-collaboration-yields-continued-success-as-further-novel-target-progressed-into-portfolio\/","og_site_name":"Pharma Trend","article_published_time":"2024-06-25T05:04:23+00:00","author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/benevolentai-and-astrazeneca-collaboration-yields-continued-success-as-further-novel-target-progressed-into-portfolio\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/benevolentai-and-astrazeneca-collaboration-yields-continued-success-as-further-novel-target-progressed-into-portfolio\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"BenevolentAI and AstraZeneca Collaboration Yields Continued Success as Further Novel Target Progressed Into Portfolio","datePublished":"2024-06-25T05:04:23+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/benevolentai-and-astrazeneca-collaboration-yields-continued-success-as-further-novel-target-progressed-into-portfolio\/"},"wordCount":624,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/benevolentai-and-astrazeneca-collaboration-yields-continued-success-as-further-novel-target-progressed-into-portfolio\/","url":"https:\/\/pharma-trend.com\/en\/benevolentai-and-astrazeneca-collaboration-yields-continued-success-as-further-novel-target-progressed-into-portfolio\/","name":"BenevolentAI and AstraZeneca Collaboration Yields Continued Success as Further Novel Target Progressed Into Portfolio - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"datePublished":"2024-06-25T05:04:23+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/benevolentai-and-astrazeneca-collaboration-yields-continued-success-as-further-novel-target-progressed-into-portfolio\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/benevolentai-and-astrazeneca-collaboration-yields-continued-success-as-further-novel-target-progressed-into-portfolio\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/benevolentai-and-astrazeneca-collaboration-yields-continued-success-as-further-novel-target-progressed-into-portfolio\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"BenevolentAI and AstraZeneca Collaboration Yields Continued Success as Further Novel Target Progressed Into Portfolio"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/59591","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=59591"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/59591\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=59591"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=59591"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=59591"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}